Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

NERV

Minerva Neurosci

NASDAQ

9.23

-0.29

-3.05%

After Hours: 9.23 0 0.00% 16:49 09/30 EDT

OPEN

9.57

PREV CLOSE

9.52

HIGH

10.28

LOW

9.09

VOLUME

624.32K

TURNOVER

52 WEEK HIGH

15.27

52 WEEK LOW

2.510

MARKET CAP

49.29M

P/E (TTM)

-1.0060

How Is The Market Feeling About Minerva Neurosciences?

Minerva Neurosciences's (NASDAQ:NERV) short percent of float has fallen 31.87% since its last report. The company recently reported that it has 1.09 million shares sold short, which is 27.55% of all regular shares that are available for trading.

Benzinga · 2d ago

10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.

Benzinga · 4d ago

NERV, FAZE: The Top 5 Short Squeeze Stocks This Week

Investor Place · 4d ago

NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week

Investor Place · 09/19 15:59

5 Short Squeeze Stocks That Could Soar: NeruoBo Pharmaceuticals, FaZe Holdings And More

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Sept. 19, according to Fintel Data:

Benzinga · 09/19 14:50

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.

Benzinga · 09/14 21:35

BRIEF-Minerva Neurosciences Files For Mixed Shelf Of Up To $200 Million

Reuters · 09/14 21:24

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported a listing transfer from

Benzinga · 09/09 20:06

About NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), seltorexant and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders.

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.